Next Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends)

News provided by

Feb 23, 2015, 07:41 ET

DUBLIN, Feb. 23, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/nbm75m/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends)" report to their offering.

No business planner in biotechnology or diagnostic equipment or services can ignore the trend of sequencing, and particularly next-generation sequencing. This technology has enabled a wide scope of research and genetic analysis. The promise of DNA sequencing has attracted many companies, researchers, and investors. DNA sequencing has already become a large market, and clinical applications of DNA sequencing are being developed and commercialized. More than ever, marketers of advanced equipment and those investing in those companies need a resource to identify the specific developments in sequencing.

This report, Next-Generation Sequencing Markets (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Trends, Platforms, Applications, Brand Ownership) provides evidence of the promise and current excitement in the DNA sequencing market.

Evidence of the promise and current excitement with DNA sequencing can be seen with many recent events:

The DNA sequencing market is growing rapidly. In October 2014, market leader Illumina raised the company's full year 2014 guidance for investors to a revenue growth for the company of approximately 30% over the previous year.
Roche and Foundation Medicine announced an agreement that is worth up to $1.2 billion. Roche agreed to acquire a majority interest in Foundation Medicine for approximately $780 million. Roche also agreed to invest $250 million in Foundation Medicine, and to fund potentially more than $150 million of R&D
Companies are raising money: In just the first part of January 2015, In addition to Roche's investment in Foundation Medicine, 10X Genomics closed a $55.5 million Series B financing and Invitae filed for an initial public offering, These follow a busy 2014 year that saw many investments in next generation sequencing companies and companies with products or services related to next generation sequencing.
Agreements with pharmaceutical companies: Companies in the pharmaceutical industry have recognized the potential benefits of next generation sequencing as a research and development tool. During just part of 2015, Genentech announced two agreements, and Pfizer announced one.
Sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model. Illumina's MiSeqDx was the first cleared in vitro diagnostic (IVD) next generation sequencing system. MiSeqDx is also CE marked, and FDA-cleared tests are currently available on this platform.

Key Topics Covered:

One: Executive Summary

Two: Introduction

Three: Sequencing Technology

Four: Sequencing Applications

Five: Deals - Sequencing Companies

Six: Applying Sequencing To Diagnostics - Market Drivers And Challenges

Seven: Dna Sequencing Market Analysis

Eight: Company Profiles: Next Generation Sequencing Companies